Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
[HTML][HTML] Early sedation with dexmedetomidine in critically ill patients
…, FE Bass, S Bin Kadiman, CJ McArthur… - … England Journal of …, 2019 - Mass Medical Soc
Background Dexmedetomidine produces sedation while maintaining a degree of arousability
and may reduce the duration of mechanical ventilation and delirium among patients in the …
and may reduce the duration of mechanical ventilation and delirium among patients in the …
[HTML][HTML] Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical …
…, FJ Martínez-Marcos, AM Mata, CJ McArthur… - BMC infectious …, 2021 - Springer
Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only for a …
investigation in numerous randomized clinical trials, but results are publicly available only for a …
Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine-2 receptor blockers on in-hospital mortality among ICU patients receiving invasive …
…, F Van Haren, E Litton, DM Mackle, CJ McArthur… - Jama, 2020 - jamanetwork.com
Importance Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H 2 RBs) are
often prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU). …
often prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU). …
Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial
Background Delayed graft function (DGF) is a major adverse complication of deceased
donor kidney transplantation. Intravenous fluids are routinely given to patients receiving a …
donor kidney transplantation. Intravenous fluids are routinely given to patients receiving a …
[HTML][HTML] Early sedation with dexmedetomidine in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE III randomised controlled trial
Purpose To quantify potential heterogeneity of treatment effect (HTE), of early sedation with
dexmedetomidine (DEX) compared with usual care, and identify patients who have a high …
dexmedetomidine (DEX) compared with usual care, and identify patients who have a high …
Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain …
BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19
Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized
with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment …
with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment …
[HTML][HTML] Effect of antiplatelet therapy on survival and organ support–free days in critically ill patients with COVID-19: a randomized clinical trial
Interventions Patients were randomized to receive either open-label aspirin (n= 565), a
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …
A randomized trial of nafamostat for Covid-19
Background Nafamostat mesylate is a potent in vitro antiviral agent that inhibits the host
transmembrane protease serine 2 enzyme used by severe acute respiratory syndrome …
transmembrane protease serine 2 enzyme used by severe acute respiratory syndrome …
